Quantifying environmental mitigation of aerosol viral load in a controlled chamber with participants diagnosed with COVID-19

Hooman Parhizkar\textsuperscript{1,2}, Leslie Dietz \textsuperscript{1,3}, Andreas Olsen-Martinez \textsuperscript{1,3}, Patrick F. Horve \textsuperscript{1,3,4}, Liliana Barnatan\textsuperscript{3}, Dale Northcutt \textsuperscript{1,2}, Kevin G. Van Den Wymelenberg \textsuperscript{1,2,3}\textsuperscript{*}

1 - Institute for Health and the Built Environment, University of Oregon, Portland, OR, United States, 97209
2 - Energy Studies in Buildings Laboratory, University of Oregon, Eugene, OR, United States, 97403
3 - Biology and the Built Environment Center, University of Oregon, Eugene, OR, United States, 97403
4 – Institute of Molecular Biology, University of Oregon, Eugene, OR, United States, 97403

*Corresponding Author: Kevin G. Van Den Wymelenberg, kevinvdw@uoregon.edu, Biology and the Built Environment Center, University of Oregon, Eugene, OR, United States, 97403, Energy Studies in Buildings Laboratory, University of Oregon, Eugene, OR, United States, 97403, Institute for Health and the Built Environment, University of Oregon, Portland, OR, United States, 97209
Summary

Environmental mitigation strategies including ventilation, filtration, and humidification significantly reduce the concentration of virus in a controlled human subject study. Smaller aerosol particles within the range of 0.3 μm -2.5 μm best characterize the variance of aerosol viral load.
Abstract

Background

Several studies indicate that COVID-19 is primarily transmitted within indoor spaces. Therefore, environmental characterization of SARS-CoV-2 viral load with respect to human activity, building parameters, and environmental mitigation strategies is critical to combat disease transmission.

Methods

We recruited 11 participants diagnosed with COVID-19 to individually occupy a controlled chamber and conduct specified physical activities under a range of environmental conditions; we collected human and environmental samples over a period of three days for each participant.

Results

Here we show that increased viral load, measured by lower RNA cycle threshold (C$_T$) values, in nasal samples is associated with higher viral loads in environmental aerosols and on surfaces captured in both the near field (1.2 m) and far field (3.5 m). We also found that aerosol viral load in far field is correlated with the number of particles within the range of 1 µm - 2.5 µm. Furthermore, we found that increased ventilation and filtration significantly reduced aerosol and surface viral loads, while higher relative humidity resulted in lower aerosol and higher surface viral load, consistent with an increased rate of particle deposition at higher relative humidity. Data from near field aerosol trials with high expiratory activities suggest that respiratory particles of smaller sizes (0.3 µm - 1 µm) best characterize the variance of near field aerosol viral load.

Conclusions

Our findings indicate that building operation practices such as ventilation, filtration, and humidification substantially reduce the environmental aerosol viral load, and therefore inhalation dose, and should be prioritized to improve building health and safety.

Keywords: SARS-CoV-2, aerosol, infectious disease, airborne, particles, ventilation, humidification, filtration
Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19), has resulted in 274,472,724 confirmed cases with more than 5,012,337 deaths globally, as of 03 November 2021[1]. There is substantial evidence that inhalation of aerosol particles containing viable SARS-CoV-2 virions is the primary route of human-to-human transmission[2–9]. Modeling of the impact of non-pharmaceutical interventions on the probability of COVID-19 infection and mortality rate [10–14] suggests that indoor congregation is the primary driver for COVID-19 disease transmission[15]. Moreover, recent comprehensive reviews highlight the importance of airborne transmission pathway via fine aerosols [16–18]. Therefore, better understanding and quantifying the relationship of human factors, design, and building operation practices on the abundance and dispersion of viral load in indoor spaces is necessary to combat disease transmission [19].

Breathing and talking are some of the human expiratory activities that have been studied to determine how these activities are associated with concentrations of viral pathogens[20,21]. These studies have contributed valuable information about the viral load of size fractionated aerosols[5,22]. In addition to human expiratory factors, indoor space design and engineering practices such as ventilation, filtration, and humidity control may influence the abundance and infectious fraction of the environmental viral load, and therefore reduce inhalation dose[22–28]. However, these indoor environmental interventions need to be studied independently through controlled experiments to quantify their impacts, while minimizing confounding variables, especially with regard to aerosols that may contain SARS-CoV-2.

In this research, we sought to better understand viral abundance and dispersion associated with differing degrees of expiratory activity, ventilation, filtration, and humidification through controlled experiments in a quasi-field setting. We measure viral RNA of SARS-CoV-2 using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) techniques as a proxy of viral load in humans and environmental aerosols and surfaces. We studied 11 human participants that were diagnosed with COVID-19 in a controlled chamber measuring 4.3 m in length, 2.8 m in width, and 2.5 m in height (28.04 m³). Our research protocol comprised a 3-day study for each participant in which human activity and environmental factors (ventilation rate, in-room filtration, humidity control) were studied as independent variables.

Methodology

A rapid deployment modular unit (RDM) was used as an environmentally controlled chamber (Figure 1) for this human participant study during Winter and Spring 2021. The study population included 11 participants between the age of 18 and 24 (Supplemental table 1). Two high-flow (200 L/min) AerosolSense air samplers (Thermo Fisher Scientific) were placed approximately 1.2 and 3.5 meters from the participants. At the end of each study period, samples from the air samplers (near, far), high-touch surfaces (phone, computer, chair), settling plates (near, far), and human specimens
(shallow nasal) were collected and transported to a BSL-2 laboratory on the University of Oregon campus in Eugene, Oregon, for further molecular analysis.

Trials were conducted in two different set-ups over three days. Trials with a S1 suffix indicate Setup-1 where both air samplers were placed next to each other for short duration and higher expiratory tests (Figure 1a). During cough trials, participants were instructed to conduct 10 uncovered coughs into an area over the air samplers, particle counters (TSI AeroTrak 9306), and CO₂ (Onset HOBO MX1102A) sensors. During speak tests, participants were instructed to conduct continuous vocalization using a standardized CDC defined passage [29] (Supplemental document, Appendix A) for 5 minutes with normal and higher amplitude at their discretion, respectively [30]. A S2 suffix indicates trials where air samplers were located at 4 ft (near field) and 11 ft (far field) of participant’s sitting position (Figure 1b). During S2 trials, participants conducted routine activities at a desk, including sitting and standing, sitting silently, sitting and participating in an online conference meeting, or were invited to walk on treadmill (physical activity day) (Figure 1b). Institutional approvals, data availability, and methods related to RDM layout, participant recruitment, sample collection, molecular analysis, and statistical analysis are described in Supplemental document, Appendix B.

Results

Near and far field aerosol samples and paired human specimens

To quantify the relationship between viral loads (RNA copies) in human nasal and aerosol samples, we paired the outcome of each aerosol sample collected with its corresponding shallow nasal sample for both near and far AerosolSense samplers during trials when participants were sitting or standing for one hour at ~0 ACH under typical ambient conditions without environmental interventions. We defined routine trials according to following conditions: 1) participants conducted typical office activity while sitting or standing for 1-hour, 2) ambient environmental conditions were maintained using only electric resistance heaters without ventilation at ~0 ACH, and 3) participants could have spontaneously coughed because of their symptoms but were not instructed to conduct any expiratory activity during routine trials. Figure 2a shows the relationship between nasal viral load and near field and far field aerosol viral load for all routine trials. Note that negative samples are defined with a C_T value of 40.

The coefficients associated with significant regression models presented in Figure 2a indicate that an increase in viral load equivalent to -1 C_T in human nasal samples is associated with increased near field viral load of -0.326 C_T (R² = 0.2276, P = 0.001092) and increased far field viral load of -0.40 C_T (R² = 0.4026, P = 1.721e-06). The difference of means between the aerosol C_T value of near field and far field aerosol samples was 1.058 C_T, indicating lower viral load for far field samples; however, the paired t-test differentiating near field and far field samples was not significant (P = 0.05955) (Figure 2b, note that black solid horizontal line represents median in all box plots). Therefore, we also report
the significant coefficient for all nasal and aerosol samples in routine trials which indicates that an increase in viral load equivalent to -1 C$_T$ in nasal samples is associated with an increase in room aerosol viral load of -0.362 C$_T$ ($R^2 = 0.3119$, $P = 1.675e-08$, Supplemental figure 1). Based upon qRT-PCR theory, a -1 C$_T$ difference is approximately equivalent to double the viral load [31]; thus, a doubling of viral load in nasal samples corresponds to a ~35% increase in aerosol viral load for samples collected in the room. To our knowledge this is the first reported relationship between environmental aerosol viral load and human viral load in a controlled environment (28,040 L$^3$ room, ~0 ACH, one-hour trials, single COVID-19 positive individual).

Furthermore, we found a statistically significant difference between the mean CO$_2$ concentration recorded at near field and far field, where CO$_2$ concentrations of near field was 80 PPM higher than in the far field ($P = 0.0004009$) (Figure 2c). Analysis of particles for routine trials indicates that there is a statistically significant difference between the number of particles collected in the range of 1 µm - 5 µm within the near field versus the far field, as summarized in Figure 2d (expanded in Supplemental figure 2). As shown in Figure 2e, we identified a significant relationship between aerosol viral load and far field particle counts within the size bin 1 µm - 2.5 µm where increased number of particles within this size bin is associated with higher aerosol viral loads ($R^2 = 0.1112$, $P = 0.04313$). The relatively low reported $R^2$ is likely due to the reality that there are many particles in the room that are not human-sourced bioaerosols, and therefore this regression should not be interpreted as an absolute prediction model. We also report a statistically significant positive correlation between the average far field CO$_2$ concentration and the number of particles of 0.3 µm - 3 µm in far field for routine trials (Supplemental figure 3) which lends more confidence in the interpretation that the observed correlation between aerosol viral load and the number of particles of 1 µm – 2.5 µm is related to bioaerosol emissions. These results provide further evidence of the importance of fine aerosols in the potential for COVID-19 disease transmission in both near and far fields.

**High-touch surfaces, settling plates, and paired human specimens**

Human specimens were compared to paired samples collected from the participants’ phone (screen), computer (adjacent to keyboard), and chair (described as high-touch surfaces), and from near field settling plates (on participant’s desk) and far field plates (adjacent to far field air sampler). Figure 3a illustrates the significant linear regressions for the viral load (RNA) on each high-touch surface relative to paired nasal samples. Figure 3b illustrates the significant linear regressions for viral load in settling plates (near and far) relative to paired nasal samples. There are no significant differences between the viral loads found in near field and far field setting plates, nor are there significant differences between any of the high-touch surfaces (Supplemental figures 4 & 5). Figure 3c illustrates the significant regressions for all sampling types relative to human nasal samples within a single figure and indicate that high-touch surfaces and aerosol samples have stronger correlations to human viral loads than settling plate surfaces. This lends more evidence that emitted virions are present in indoor spaces within smaller particles that remain as aerosols for long time periods.
High expiratory activity, particles, and aerosol viral load

We find a significant correlation between aerosol viral load associated with high expiratory activities and paired nasal samples where an increase in viral load equivalent to -1 Ct in human nasal samples is associated with increased immediate field (<1m, Figure 1a) aerosol viral loads as follows: -0.189 Ct ($R^2 = 0.09058, P = 0.0225$) for 1-minute cough tests, -0.271 Ct ($R^2 = 0.1979, P = 0.00115$) for 5-minute speaking tests, and -0.229 Ct ($R^2 = 0.1796, P = 0.00141$) for 5-minute speaking loudly tests (Supplemental figure 6). Furthermore, we find a significant positive relationship between the mean number of immediate field particles during high expiratory activities (Setup 1) in the size ranges 0.3 µm -1 µm (Figure 4a), 1 µm -2.5 µm (Figure 4b), and 10 µm -25 µm (Figure 4e) and the viral load in the immediate field aerosols, while the other particle size bins are not significant (Figure 4). We provided further analysis of the relationship between different respiratory activities and viral loads in Supplemental figures 7 & 8. Further discussion about the relationship between aerosol viral loads and particles of different size bins are provided in the Supplemental document, Appendix C.

The impact of ventilation and filtration on aerosol and surface viral load

Indoor air exchange rate, measured in Air Changes per Hour (ACH), has previously been demonstrated to reduce indoor particles and therefore hypothesized to reduce the concentration of viral aerosols, corresponding inhalation dose, and consequently the probability of indoor occupants acquiring infection[16,32–34]. Few studies have measured the relationship between ventilation, filtration and aerosol viral load[35]. Therefore, we investigated the impact of alternate air exchange rates, using 100% outside air (OSA) and filtration levels during removal mechanism trials. As shown in Table 1, each removal mechanism day began with a baseline ~0 ACH trial, followed by four 100% OSA ventilation trials (two at ~9 ACH and two at ~3 - 4.5 ACH) provided by an exhaust fan (fitted with HEPA filter for infection control). Thereafter, a single trial with two in-room HEPA filters (without OSA) was conducted. All removal mechanism trials and the ~0 ACH control trials were conducted for a duration of one hour. We found a significant difference between control trials and all removal mechanism trials ($P = 0.029$, Figure 5a). In Figure 5a we show a significant difference between control trials and paired removal mechanism trials, while in Figure 5b we show a significant correlation for all control trials at ~0 ACH and all ventilation trials with 100% OA organized by mean CO$_2$ concentration. Trials with less than ~4.5 ACH (including ~0 ACH trials) were associated with significantly higher aerosol viral loads in the near field when compared with trials greater than ~9 ACH, with a mean difference of -3.6 Ct ($P = 0.037$, unpaired t-test, Figure 5c). Even though the mean difference of aerosol viral load in the far field for trials with less than ~4.5 ACH (including ~0 ACH trials) was higher than trials with greater than ~9 ACH, we did not observe a statistically significant difference for far field aerosol viral load ($P = 0.085$, unpaired t-test, Figure 5c). When examining total room aerosol viral load (near field and far field together), we report that trials with less than ~4.5 ACH (including ~0 ACH trials) were associated with statistically higher viral load than trials with greater than ~9 ACH, with a mean difference of -3.2 Ct ($P = 0.01153$, unpaired t-test, Supplemental figure 9). Our research provides further evidence that improved ventilation and filtration is beneficial for both near field and far field aerosol viral load (Supplemental table 2). Given these
relationships within this room (Figure 5b), ventilation trials indicate that an increase in ~128 PPM of CO₂ concentration corresponds with an increase in aerosol viral load equivalent to -1 Ct, thus, approximately a doubling of the viral load. Moreover, filtration trials indicate that there is a significant difference between trials with only in-room HEPA filtration (~1000 m³/hr) and paired control trials at ~0 ACH, where HEPA trials have lower viral load equivalent to 3.24074 Cₜ (P = 0.029), thus, approximately an order of magnitude reduction (Figure 5d).

Our results provide evidence that increased air exchange (~9 ACH with 100% OSA) or in-room HEPA filtration (~1000 m³/hr) yields reduced aerosol viral load, and reason therefore suggests these measures are likely to reduce inhalation dose and the probability of infection in indoor spaces. We found no statistical difference between aerosols captured during control trials with ~0 ACH and those with ~3 – 4.5 ACH; however, this may be related to limitations in sample size. Among three types of high-touch surfaces collected in this study, increased ACH was associated with lower viral load on participant’s computers, with a mean difference of 4.033 Cₜ (P = 0.002323) whereas phone and chair samples showed no significant difference with air exchange rate (Supplemental figure 10).

Relative humidity and aerosol viral load

Relative humidity is hypothesized to impact aerosol pathogens and disease transmission in three ways; (1) improved human immune response[33] (2) reduced viability in aerosols at RH between 40-60%[15,23], and (3) increased particle deposition[16,36]. The structure and behavior of aerosol pathogens, specifically particle size, settling rate, and diffusion, are each affected by RH[36,37]. In this study, we aimed to measure environmental viral load at different RH conditions. Two dehumidifiers and two humidifiers were used to regulate RH to low (22.2% - 38.9%, mean = 28.8%) and high (44.83 % - 61%, mean = 53.9%) levels during the “relative humidity” trials. Each participant’s relative humidity day started with a 1-hour control trial with ~0 ACH and RH at ambient conditions, followed by two 1-hour dehumidification trials and two 1-hour humidification trials. Room aerosol Cₜ values were paired with mean RH values (ranging from 20-70%) recorded for each trial.

Relative humidity trials indicate that an increase of ~11.85% in RH corresponds with a decrease in aerosol viral load equivalent to 1 Cₜ (p = 0.008), thus, approximately a 50% reduction in aerosol viral load, as shown in (Figure 6a). Similarly, an increase of ~10.02% in RH corresponds with an increase in surface (chair, computer, phone) viral load equivalent to -1 Cₜ (p = 0.01) as shown in Figure 6c, consistent with increased particle deposition. Figure 6b shows the significant decrease in aerosol viral load equivalent to 3.289 Cₜ (paired t-test, P = 0.0002643) for humidification trials as compared to dehumidification trials. Conversely, Figure 6d shows the significant increase in computer surface viral load equivalent to -2.873 Cₜ (paired t-test, P = 0.01593) for humidification trials as compared to dehumidification trials.
This is one of the first studies that investigated the role of relative humidity on viral RNA in aerosols and surfaces in a realistic setting. Our results suggest that increased RH corresponds with decreased viral load in aerosols and increased viral load on select indoor surfaces, consistent with an increased rate of particle deposition. Since several studies have demonstrated that there is a substantially higher risk for aerosol mediated transmission than fomite mediated transmission[38], active humidity control (including humidification, or reduced dehumidification) could be implemented to reduce aerosol mediated COVID-19 transmission risk reduction in indoor spaces. Of course, humidification controls must be properly maintained and managed to avoid condensation and mold propagation.

**Conclusion and Limitations**

All participants were given the opportunity to opt out of the study at any time, thus two subjects only completed the first day of study. There were some modest inconsistencies between trial durations in order to accommodate participants’ needs. Not all participants walked on the treadmill, and some walked at different speeds or for different durations. Participants may have presented inconsistent symptoms (such as coughing) during the course of the experiments; however, the control trial at the beginning of each day addresses a substantial part of this limitation. While this was an extensive study design, conducted over three days per participants (Supplemental figures 11 & 12), the total number of unique participants (n=11), and limited age range (18-24 years of age) of participants, presents some limitations to generalizability. RNA samples were not assessed for viability.

In summary we found statistically significant:

1- positive relationships between viral load (RNA) found in human specimens and paired aerosol and surface samples at ~0 ACH and ambient conditions for sitting and standing trials (routine trials) as well as trials with high expiratory activities (coughing, speaking, and speaking loudly);

2- positive relationship between viral load in near field aerosols captured during periods of higher expiratory activity and near field particles of 0.3 μm -1 μm, 1 μm -2.5 μm, and 10 μm - 25 μm in size, but no statistical significance for 2.5 μm -10 μm particles;

3- increased CO₂ concentrations and particle counts in the range of 1-5 μm measured in the near field as compared to the far field for routine trials;

4- positive relationship between aerosol viral load in the far field and the number of corresponding far field particles detected in the range of 1-2.5 μm;
5- inverse relationships between viral load found in aerosols and degree of ventilation, as well as in-room filtration;

6- relationships between viral load and degree of relative humidity; whereby higher RH is associated with lower viral load in aerosol samples and higher viral load in select surface samples, consistent with increased particle deposition on surfaces.
NOTES

Acknowledgments

The authors would like to thank all staff in the BioBE Center, including Garis Bowles, Georgia MacCrone, Jackson Mestler, Dan Richards, and Vincent Moore. The authors would like to thank countless individuals at the University of Oregon for helping to make this research design possible. The authors would also like to thank Dr. Richard Corsi, Dr. Siobhan Rockcastle, and Dr. Mark Fretz for their input during results analysis. Most importantly, we would like to thank all study participants for their commitment during a difficult period in their lives. All data and code supporting this study and required to create the analyses are provided in Github, available at https://github.com/BioBE/RDM

Author contributions:

KGVDW performed funding acquisition and managed the investigation team. KGVDW and HP conceived of project scope and methodology with input from LD and PFH. KGVDW and LD enrolled and consented study participants. DN worked with all other authors to set up modular room and all research instrumentation. HP, LB, LD, and AOM collected biological specimens. LB, LD, PFH, AOM performed laboratory analyses. HP performed data curation, data exploration, developed final analysis scripts, performed final analysis, and created visualizations with support from all authors. HP developed the original manuscript with direction and input from KGVDW. All authors provided manuscript revisions and edits on subsequent manuscript drafts and approved final manuscript.

Funding

This research was funded by Thermo Fisher Scientific under award number 4133V1. The funder provided the university with support in the form of salaries for all authors, equipment, and reagents but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. However, per contractual obligations, the funder had the right to review the final manuscript for confidential information prior to submission.

Competing interests:

KGVDW has a company called Duktile that provides consulting related to healthy buildings and pathogen control. KGVDW also serves as a scientific advisor to EnviralTech and Poppy, both are companies that conduct viral environmental surveillance and infection control. KGVDW reports honorarium for a lecture about building mitigation strategies inclusive of 5+ papers written by our research team from Pacific Gas & Electric. PFH serves as Director of Resource Archiving for the Microbes and Social Equity Working Group. LD serves at Eugene chapter lead for the 500 Women Scientists group. KGVDW also serves as scientific advisor to the Integrated Bioscience and Built Environment Consortium (IBEC). LGD reports being Chapter Leader of 500WomenScientists, unpaid. None of these organizations (Duktile, EnviralTech, Poppy, IBEC, 500 Women Scientists and the
Microbes and Social Equity Working Group) played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other authors have any competing interests to disclose.
1. Coronavirus disease (COVID-19) – World Health Organization. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=CjwKCAjw7--KBhAMEiwAxfpkWI8fJtpz2fXY5q0AxU1ILGFRSC9pYbiemoXwCtoieyEPt8tOWcRmBoCKmsQAvD _BwE. Accessed 5 October 2021.

2. Anderson EL, Turnham P, Griffin JR, Clarke CC. Consideration of the aerosol transmission for COVID-19 and public health. Risk Anal 2020; 40:902–907.

3. Ma J, Qi X, Chen H, et al. Coronavirus disease 2019 patients in earlier stages exhaled millions of severe acute respiratory syndrome Coronavirus 2 per hour. Clin Infect Dis 2021; 72:e652–e654.

4. Zhou L, Yao M, Zhang X, et al. Breath-, air- and surface-borne SARS-CoV-2 in hospitals. J Aerosol Sci 2021; 152:105693.

5. Santarpia JL, Herrera VL, Rivera DN, et al. The size and culturability of patient-generated SARS-CoV-2 aerosol. J Expo Sci Environ Epidemiol 2021; :1–6.

6. Tang JW, Bahnfleth WP, Bluysen PM, et al. Dismantling myths on the airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Hosp Infect 2021; 110:89–96.

7. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271–280.e8.

8. Prather KA, Marr LC, Schooley RT, McDiarmid MA, Wilson ME, Milton DK. Airborne transmission of SARS-CoV-2. Science 2020; 370:303–304.

9. Morawska L, Milton DK. It is time to address airborne transmission of Coronavirus disease 2019 (COVID-19). Clin Infect Dis 2020; 71:2311–2313.

10. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584:257–261.

11. Azimi P, Keshavarz Z, Cedeno Laurent JG, Stephens B, Allen JG. Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission. Proc Natl Acad Sci U S A 2021; 118:e2015482118.

12. Pei S, Kandula S, Shanan J. Differential effects of intervention timing on COVID-19 spread in the United States. Sci Adv 2020; 6:eabd6370.

13. Mathai V, Das A, Bailey JA, Breuer K. Airflows inside passenger cars and implications for airborne disease transmission. Sci Adv 2021; 7:eabe0166.

14. Parhizkar H, Van Den Wymelenberg KG, Haas CN, Corsi RL. A quantitative risk estimation platform for indoor aerosol transmission of COVID-19. Risk Anal 2021; Available at: http://dx.doi.org/10.1111.risa.13844.

15. Qian H. Indoor transmission of SARS-CoV-2. Indoor Air 2020; :12766.
16. Wang CC, Prather KA, Sznitman J, et al. Airborne transmission of respiratory viruses. Science 2021; 373:eabd9149.

17. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci U S A 2020; 117:14857–14863.

18. Bazant MZ, Bush JW. A guideline to limit indoor airborne transmission of COVID-19. Proc Natl Acad Sci U S A 2021; 118. Available at: https://www.pnas.org/content/118/17/e2018995118. Accessed 20 October 2021.

19. Morawska L, Allen J, Bahnfleth W, et al. A paradigm shift to combat indoor respiratory infection. Science 2021; 372:689–691.

20. Edwards DA, Ausiello D, Salzman J, et al. Exhaled aerosol increases with COVID-19 infection, age, and obesity. Proc Natl Acad Sci U S A 2021; 118:e2021830118.

21. Coleman KK, Tay DJW, Sen Tan K, et al. Viral load of SARS-CoV-2 in respiratory aerosols emitted by COVID-19 patients while breathing, talking, and singing. Clin Infect Dis 2021; Available at: http://dx.doi.org/10.1093/cid/ciab691.

22. Dietz L, Horve PF, Coil DA, Fretz M, Eisen JA, Van Den Wymelenberg K. 2019 novel Coronavirus (COVID-19) pandemic: Built environment considerations to reduce transmission. mSystems 2020; 5. Available at: http://dx.doi.org/10.1128/mSystems.00245-20.

23. Dabisch P, Schuit M, Herzog A, et al. The influence of temperature, humidity, and simulated sunlight on the infectivity of SARS-CoV-2 in aerosols. Aerosol Sci Technol 2021; 55:142–153.

24. Doremalen N, T B, Dh M, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. 2020;

25. Kim SW, Ramakrishnan MA, Raynor PC, Goyal SM. Effects of humidity and other factors on the generation and sampling of a coronavirus aerosol. Aerobiologia (Bologna) 2007; 23:239–248.

26. Chan KH, Peiris JSM, Lam SY, Poon LLM, Yuen KY, Seto WH. The effects of temperature and relative humidity on the viability of the SARS Coronavirus. Adv Virol 2011; 2011:734690.

27. Li Y, Leung GM, Tang JW, et al. Role of ventilation in airborne transmission of infectious agents in the built environment - a multidisciplinary systematic review. Indoor Air 2007; 17:2–18.

28. de Man P, Paltansing S, Ong DSY, Vaessen N, van Nielen G, Koelman JGM. Outbreak of Coronavirus disease 2019 (COVID-19) in a nursing home associated with aerosol transmission as a result of inadequate ventilation. Clin. Infect. Dis. 2021; 73:170–171.

29. Available at: https://www.cdc.gov/niosh/npptl/stps/pdfs/RCT-APR-0067-508.pdf. Accessed 11 September 2021.

30. Fairbanks G. Voice and Articulation Drillbook. Laryngoscope 1941; 51:1141.

31. Jia Y. Real-Time PCR. In: Conn PM, ed. Methods in Cell Biology. San Diego, CA: Elsevier, 2012: 55–68.

32. Allen JG, Ibrahim AM. Indoor air changes and potential implications for SARS-CoV-2 transmission. JAMA 2021; 325:2112–2113.
33. Dietz L, Horve PF, Coil DA, Fretz M, Eisen JA, Van Den Wymelenberg K. Correction for Dietz et al., “2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission.” mSystems 2020; 5. Available at: http://dx.doi.org/10.1128/mSystems.00375-20.

34. Klompas M, Baker MA, Rhee C. Airborne transmission of SARS-CoV-2: Theoretical considerations and available evidence. JAMA 2020; 324:441–442.

35. Horve P, Dietz L, Bowles G, et al. Longitudinal analysis of built environment and aerosol contamination associated with isolated COVID-19 positive individuals. 2021; Available at: https://assets.researchsquare.com/files/rs-861942/v1_covered.pdf?c=1630438371.

36. Hänel G. Humidity effects on gravitational settling and Brownian diffusion of atmospheric aerosol particles. Pure Appl Geophys 1977; 115:775–797.

37. Chaudhuri S, Basu S, Saha A. Analyzing the dominant SARS-CoV-2 transmission routes toward an ab initio disease spread model. Phys Fluids (1994) 2020; 32:123306.

38. Rocha ALS, Pinheiro JR, Nakamura TC, et al. Fomites and the environment did not have an important role in COVID-19 transmission in a Brazilian mid-sized city. Sci Rep 2021; 11:15960.
FIGURE LEGENDS:

Figure 1 Rapid deployment modular unit (RDM), a) higher expiratory trials (S1), b) regular trials (S2)

Figure 2 a) The correlation of near field (1.2 m) or far field (3.5 m) aerosol viral loads (RNA) with corresponding human nasal samples during routine trials b) comparison of near field and far field aerosol viral loads for routine trials, c) comparison of mean CO2 concentrations in the near field and far field for routine trials, d) paired t-tests for all particle size bins at near field and far field for routine trials, e) correlation between mean far field aerosol viral loads and the corresponding mean concentration of far field particles for routine trials.

Figure 3 a) viral load (RNA) on each high-touch surface relative to paired nasal samples, b) viral load (RNA) on settling plates at near and far field relative to paired nasal samples, c) The correlation of each sample type (Aerosol, high touched surfaces, and settling plates) to paired nasal sample.

Figure 4 Linear correlation between CT value and particles for a) 0.3-1 µm particles, b) 1-2.5 µm particles, c) 2.5-3 µm particles, d) 3-5 µm particles, e) 5-10 µm particles, and f) 10-25 µm particles.

Figure 5 The impact of ventilation and filtration on CT value of aerosol samples, a) match paired comparison between trials with removal mechanism trials (filtration and ventilation) and control trials with ~0 ACH, b) linear correlation between aerosol CT value and paired mean CO2 concentration affected by only ventilation (same physical activities), c) Comparison of aerosol CT for ventilation trials of under ~4.5 ACH and above ~9 ACH in near field and far field, d) match paired comparison of aerosol CT for trials with in-room HEPA filtration and corresponding control trials with ~0 ACH.

Figure 6 a) Correlation between aerosol CT value and mean relative humidity among dehumidification, humidification, and control trials b) paired comparison of aerosol CT between Dehumidification and Humidification trials, c) Correlation between surface CT value and mean relative humidity among dehumidification, humidification, and control trials, d)) paired comparison of select surface (computer) CT between Dehumidification and Humidification trials.
| Set-up | 1. Physical activity                  | 2. Removal mechanism                  | 3. Relative humidity (RH) |
|--------|--------------------------------------|--------------------------------------|--------------------------|
| S1     | 10 coughs in 1 minute                | 10 coughs in 1 minute                | 10 coughs in 1 minute    |
| S1     | Speak for 5 minutes                  | Speak for 5 minutes                  | Speak for 5 minutes      |
| S1     | Speak loudly for 5 minutes           | Speak loudly for 5 minutes           | Speak loudly for 5 minutes|
| S2     | 1-hour regular sitting               | 1-hour regular sitting               | 1-hour regular sitting   |
| S2     | 1-hour standing                      | 1-hour sitting at ~9 ACH             | 1-hour sitting at low RH |
| S2     | 30-min sitting silently              | 1-hour sitting at ~3 ACH             | 1-hour sitting at low RH |
| S2     | 30-min sitting speaking              | 1-hour sitting at ~9 ACH             | 1-hour sitting at high RH|
| S2     | 15-min walking on treadmill           | 1-hour sitting at ~4.5 ACH           | 1-hour sitting at high RH|
| S2     |                                      | 1-hour sitting with HEPA filtration  |                          |
Legend
1 - Far field AerosolSense
2 - Close field AerosolSense
3 - Particle counter
4 - CO₂ onset
5 - Far field settling plate
6 - Close field settling plate
7 - Computer
8 - Chair
9 - In room HEPA filters
10 - Dehumidifiers
11 - Humidifiers *
12 - Treadmill
13 - HEPA exhaust
14 - Heaters *

* Only one object of this kind is visible in this figure
Figure 3

(a) and (b) show scatter plots with linear regression lines. The plots compare C\textsubscript{i} values of paired nasal samples with C\textsubscript{o} values from different locations (Chick, Core, and Mouse) and methods (Near, Far, and Field). The p-values are provided for each comparison:

- (a): P = 0.0501 (Chick), P = 0.004579 (Core), P = 0.0363 (Mouse)
- (b): P = 0.6174 (Far field), P = 0.0153 (Near field)

(c) presents a similar scatter plot but with a different set of locations and methods (Near, Far, Field). The legend for the different types (Chick, Core, Mouse, Near, Far, Field) is shown in the right margin.
Figure 4

(a) $R^2 = 0.003153 \quad x = 6.48 \times 10^{-3} - 1.01 \times 10^{-2} \quad R^2 = 0.10$

(b) $x = 4.14 \times 10^{-2} - 0.19 \quad R^2 = 0.05$

(c) $P = 0.0074 \quad x = 258 - 4.76 \quad R^2 = 0.03$

(d) $P = 0.0056 \quad x = 368 - 5.63 \quad R^2 = 0.02$

(e) $P = 0.1513 \quad x = 228 - 5.97 \quad R^2 = 0.06$

(f) $P = 0.0324 \quad x = 33.1 - 1.967 \quad R^2 = 0.04$
Figure 5

(a) Box plots showing the distribution of CO$_2$ levels under different conditions. $n = 120, P = 0.020$.

(b) Scatter plot illustrating the relationship between ventilation and CO$_2$ concentration (PPM). $P = 0.004551$.

(c) Box plots comparing CO$_2$ levels in the far field and near field conditions. $n = 36, P = 0.0016$.

(d) Box plots depicting CO$_2$ levels under different ventilation and filtration conditions. $n = 36, P = 0.0024$. 

Trial categories include Control and Filtration.
Figure 6

(a) 

(b) 

(c) 

(d)